HUGEL, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 223,000 KRW | -1.11% |
|
-2.62% | +49.26% |
| Jul. 01 | Hugel Inc. and BENEV Company Inc. Announce Strategic Partnership in the U.S. Market | CI |
| Jun. 28 | Tranche Update on Hugel, Inc.'s Equity Buyback Plan announced on March 27, 2024. | CI |
Hugel Inc is a Korea-based company mainly engaged in the manufacture of biopharmaceuticals. The Company's product portfolio consists of botulinum toxins which used for treatment of benign essential blepharospasm and temporary improvement of moderate to severe glabellar lines including 50 unit types, 100 unit types and 200unit types; hyaluronic acid (HA) fillers which used for temporary removal of facial wrinkles including the chaeum premium No.1, the chaeum premium No.2, the chaeum premium No.3m the chaeum premium No.4, the chaeum MID 20A, the chaeum DEEP 20A, the chaeum SUB-Q 20A and the chaeum VOLUS 20A; wellages, blue roses and other cosmetics. The Company sells its products in domestic and overseas markets.
Sector
Pharmaceuticals
Calendar
2024-08-12
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
223,000
KRW
Average target price
260,556
KRW
Spread / Average Target
+16.84%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +49.26% | 1.8B | |
| +7.86% | 101B | |
| +7.76% | 42.63B | |
| -14.37% | 33.5B | |
| +82.32% | 29.77B | |
| -12.27% | 16.14B | |
| +2.33% | 14.31B | |
| -8.56% | 11.55B | |
| +182.74% | 10.53B | |
| +3.67% | 9.2B |
- Stock Market
- Equities
- A145020 Stock
- News Hugel, Inc.
- Hugel to Retire 54.6 Billion Won Treasury Shares
